Shares of biotechnology firm Geron experienced significant volatility following the presentation of new clinical data at the American Society of Hematology (ASH) annual meeting. The immediate market response was negative, with the stock declining 3.05% to close at $1.27, despite the release of positive long-term results for its flagship therapy, RYTELO (imetelstat).
Analyst Consensus Points to Significant Undervaluation
The current stock price movement stands in stark contrast to the perspective of market observers. A consensus price target of $3.00, derived from seven analysts, suggests an upside potential of more than 130% from present levels. The unanimous “Buy” rating indicates that institutional experts view the equity as undervalued, particularly in light of the recent clinical updates. This bullish outlook persists even as the company’s market capitalization sits at approximately $810.71 million, with a reported net loss of $79.99 million over the past twelve months.
Surprising Biomarker Correlation Emerges from Data
Detailed findings presented on December 8 revealed a notable and somewhat paradoxical correlation in the treatment of lower-risk myelodysplastic syndromes (LR-MDS). A post-hoc analysis of the Phase 3 IMerge study indicated that patients who experienced certain therapy-related cytopenias early in their treatment course demonstrated superior clinical outcomes.
Should investors sell immediately? Or is it worth buying Geron?
Specifically, patients who showed a pronounced reduction in neutrophils (≥75%) or platelets (≥50%) within the first two treatment cycles achieved higher rates of transfusion independence. These patients also exhibited a greater increase in hemoglobin levels. This suggests that specific early-onset adverse events could potentially serve as biomarkers for the drug’s ultimate efficacy.
Long-Term Survival Benefits Observed
The updated dataset includes a median follow-up period of 45 months, revealing favorable trends across several key endpoints:
* Overall Survival (OS): A positive trend was observed compared to the placebo group.
* Progression-Free Survival (PFS): The data showed a favorable development.
* AML Progression: The time to progression to acute myeloid leukemia was prolonged.
While the study was not originally powered to demonstrate a statistically significant improvement in overall survival as a primary endpoint, the consistent data across various patient subgroups points to a sustained clinical benefit.
Ad
Geron Stock: Buy or Sell?! New Geron Analysis from December 9 delivers the answer:
The latest Geron figures speak for themselves: Urgent action needed for Geron investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 9.
Geron: Buy or sell? Read more here...
